Contract Manufacturing &
Compliance FAQ Center.
Direct, transparent answers to critical manufacturing questions for brand founders and procurement directors: from MOQ thresholds and IP formula ownership to commercial lead times and analytical COA release protocols.
Our standard entry MOQ for capsule manufacturing is typically 100,000 capsules (equivalent to ~1,660 bottles at 60 count, or ~3,330 bottles at 30 count). For compressed tablets, our production run minimum is 150,000 to 250,000 tablets depending on tooling and coating complexity. For high-growth emerging brands, pilot batch programs are available upon technical review.
You own 100% of your custom formulation IP. At MNL, we operate under strict mutual Non-Disclosure Agreements (NDAs). When you commission custom R&D or transfer an existing recipe to our labs, your proprietary formula remains your exclusive asset. We do not manufacture competing proprietary house brands using client intellectual property.
Yes, without exception. Every single commercial lot manufactured at our Carrollton or Van Alstyne facilities is accompanied by an individualized, lot-numbered Certificate of Analysis (COA). The COA documents physical properties, active potency assays (HPLC), heavy metal screens (ICP-MS for Pb, As, Cd, Hg), and full microbiological enumeration (TPC, Yeast & Mold, Salmonella, E. coli).
Have a Complex Formulation or Specific Custom Requirement?
Every dietary supplement product line is unique. If your question involves patented branded ingredients, non-standard packaging formats, or specialized accelerated stability testing, our R&D chemists are ready to assist.